CAPR
Capricor Therapeutics, Inc.·Healthcare
29.14
0.749%(−0.22)
Close PriceLast Updated: — ET
52W L: $4.3052W H: $40.37
CAPR NEWS
seekingalpha.com
May 12
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
marketbeat.com
May 12
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku.
globenewswire.com
May 12
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints GMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected Cash balance of approximately $279 million expected to support operations into Q4 2027 Eligible for a Priority Review Voucher upon approval; PRV is transferable and monetizable, offering potential non-dilutive capital Conference call and webcast today at 4:30 p.m.
fool.com
May 10
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.
benzinga.com
May 8
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor Therapeutics Inc. (NASDAQ:CAPR) on Thursday filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma, Inc., alleging that flaws in the companies' U.S. distribution agreement for experimental Duchenne muscular dystrophy treatment Deramiocel could limit patient access to the therapy.
globenewswire.com
May 4
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026.
